CAPR
NASDAQ · Biotechnology
Capricor Therapeutics Inc
$29.10
-2.07 (-6.64%)
Financial Highlights (FY 2026)
Revenue
30.52M
Net Income
-55,455,340
Gross Margin
—
Profit Margin
-181.7%
Rev Growth
+352.7%
D/E Ratio
0.02
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | 43.5% | 43.5% | 43.5% |
| Operating Margin | -191.1% | 20.6% | 21.1% | 23.0% |
| Profit Margin | -181.7% | 19.3% | 19.4% | 19.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 30.52M | 187.20M | 168.99M | 200.90M |
| Gross Profit | — | 81.41M | 73.48M | 87.36M |
| Operating Income | -58,327,770 | 38.52M | 35.59M | 46.23M |
| Net Income | -55,455,340 | 36.18M | 32.84M | 38.17M |
| Gross Margin | — | 43.5% | 43.5% | 43.5% |
| Operating Margin | -191.1% | 20.6% | 21.1% | 23.0% |
| Profit Margin | -181.7% | 19.3% | 19.4% | 19.0% |
| Rev Growth | +352.7% | +21.4% | +1.7% | +17.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 18.29M | 560.43M | 596.69M | 549.88M |
| Total Equity | 788.21M | 433.52M | 435.03M | 413.42M |
| D/E Ratio | 0.02 | 1.29 | 1.37 | 1.33 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -56,521,974 | 59.64M | 51.36M | 64.78M |
| Free Cash Flow | — | 19.67M | 27.43M | 19.13M |